Focused On-demand Library for Cell cycle control protein 50B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q3MIR4

UPID:

CC50B_HUMAN

Alternative names:

P4-ATPase flippase complex beta subunit TMEM30B; Transmembrane protein 30B

Alternative UPACC:

Q3MIR4; B3KR84; Q14D00

Background:

Cell cycle control protein 50B, also known as TMEM30B, is a critical component of the P4-ATPase flippase complex. This complex plays a pivotal role in maintaining the asymmetric distribution of phospholipids across membranes by transporting aminophospholipids from the outer to the inner leaflet. This process is essential for vesicle formation and the uptake of lipid signaling molecules, with TMEM30B assisting in substrate binding and facilitating the export of alpha subunits from the ER to the plasma membrane.

Therapeutic significance:

Understanding the role of Cell cycle control protein 50B could open doors to potential therapeutic strategies. Its involvement in phospholipid translocation and membrane asymmetry is fundamental to cellular processes, suggesting that modulation of its activity could have therapeutic implications.